Cargando…
1290. Real-World Experience with Omadacycline for Nontuberculous Mycobacterial and Gram-Negative Infections: A Multicenter Evaluation
BACKGROUND: Omadacycline (OMC) is an aminomethylcycline antibiotic in the tetracycline class that has been Food and Drug Administration-approved for acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia. OMC has been shown to have potent in vitro activity agai...
Autores principales: | Morrisette, Taylor, Philley, Julie V, Sigler, Carly, Frens, Jeremy J, Webb, Andrew J, Stevens, Ryan W, Howard, Catessa, Bouchard, Jeannette, Bookstaver, P B, Barger, Melissa, Lagnf, Abdalhamid M, Alosaimy, Sara, Rybak, Michael J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776159/ http://dx.doi.org/10.1093/ofid/ofaa439.1473 |
Ejemplares similares
-
1082. Real-World Experience with Omadacycline for Nontuberculous Mycobacterial Infections: A Multicenter Evaluation
por: Morrisette, Taylor, et al.
Publicado: (2021) -
Preliminary, Real-world, Multicenter Experience With Omadacycline for Mycobacterium abscessus Infections
por: Morrisette, Taylor, et al.
Publicado: (2021) -
Real-World, Multicenter Case Series of Patients Treated with Oral Omadacycline for Resistant Gram-Negative Pathogens
por: Morrisette, Taylor, et al.
Publicado: (2022) -
1422. A Multi-Center Evaluation of Omadacycline for Multi-Drug Resistant Infections
por: Ghali, Amer El, et al.
Publicado: (2022) -
Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomes
por: El Ghali, Amer, et al.
Publicado: (2023)